An observational study in Critical Illness, Diabetes Mellitus and Acid-Base Imbalance, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Assiut University · Observational
Among 32 studies in Diabetes Mellitus by Assiut University — 20 open to participants now, 20 under way, none of them phase 3. Diabetes Mellitus · Assiut University.
Among the 32 studies in Diabetes Mellitus by Assiut University, this one is the 16th largest by planned enrollment of the 28 observational ones that give a count, is one of 6 that started in 2026, is one of 28 observational ones, reaches primary completion later than 16 of the 19 other live ones, and was the 29th registered.
8,291 studies on the registry are indexed under Diabetes Mellitus; 1,077 are open to participants now.
Browse Diabetes Mellitus studies →20 of the 32 studies in Diabetes Mellitus by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University · Sites in Egypt
Assiut University · Sites in Egypt
Assiut University
Ages 18+
Assiut University
Ages 18+
Assiut University
Ages 18+
By country, each count listing its studies:
Of the 651 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 198 (30%) stop at 75 or younger; 87 take children under 18; 183 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 246 across 1,936 observational studies indexed under Diabetes Mellitus.
Median enrollment 93 across the 4 interventional studies, 108 across the 28 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,079 studies on the registry; 2,177 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
8 of the studies in Diabetes Mellitus by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06691997Assiut UniversityThe Impact of Glycemic Control on Rheumatoid Arthritis Disease Activity on Diabetic Patients | 2026-11-14 |
| NCT07306884Assiut UniversityNeurophysiological, Autonomic, and Sonographic Assessment of Diabetic Peripheral Neuropathy | 2027-01 |
| NCT07343648Assiut UniversityAssessment of Antithyroglobulin Antibody Levels Among Diabetic Patients | 2027-02 |
| NCT07204782Assiut UniversityCardiovascular Disease CVD Constitutes a Significant Health Challenge for Individuals With Type 2 Diabetes Mellitus T2DM, Affecting Approximately 32% of This Population and Contributing Significantly to Global Mortality.Visceral Adipose Tissue VAT Accumulation Has Been Recognize | 2027-04-01 |
| NCT07821814Assiut UniversityLeukocyte Glucose Index and Severity of Diabetic Ketoacidosis | 2027-09-10 |
Add all 8 to your calendar (.ics) → With an account.
Among the 32 studies in Diabetes Mellitus by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Frequent monitoring of acid-base status, ventilation, and tissue oxygenation is essential for managing critically ill patients in the intensive care unit (ICU). While arterial blood gas (ABG) analysis is considered the standard method for these evaluations, maintaining arterial catheters carries risks of complications, such as thrombosis, hematoma, and infection. Central venous blood gas (CVBG) analysis offers a safer alternative because central venous catheters are already routinely placed for patient care. Additionally, the venous-to-arterial carbon dioxide difference (CO2 gap) serves as an indicator of systemic blood flow and tissue perfusion.
However, patients with diabetes mellitus often present with underlying microvascular alterations, endothelial changes, and metabolic variations that might alter tissue perfusion and peripheral gas exchange. This study aims to assess the correlation and agreement between central venous and arterial blood gas parameters, as well as evaluate the diagnostic accuracy of the CO2 gap, in diabetic versus non-diabetic critically ill patients.
A total of 100 adult ICU patients (50 diabetic and 50 non-diabetic) with pre-existing central venous and arterial lines will be enrolled. Paired blood samples will be drawn simultaneously to compare blood gas values and calculate the CO2 gap without altering standard clinical treatment.
8,291 studies on the registry are indexed under Diabetes Mellitus; 1,077 are open to participants now.
This study's planned enrollment of 100 is below the median of 246 across 1,936 observational studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Assiut University is the lead sponsor of 5,079 studies on the registry; 2,177 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Compared within Diabetes Mellitus, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Adult critically ill patients (both diabetic and non-diabetic) admitted to the Critical Care Unit of the Internal Medicine Department at Assiut University Hospital who have standard clinical indications for indwelling central venous catheters and arterial lines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Critically ill adult patients admitted to the intensive care unit who have a confirmed diagnosis of Diabetes Mellitus. All participants undergo simultaneous paired arterial and central venous blood gas sampling to evaluate agreement and CO2 gap dynamics.
Critically ill adult patients admitted to the intensive care unit without a history or diagnosis of Diabetes Mellitus. All participants undergo simultaneous paired arterial and central venous blood gas sampling to evaluate agreement and CO2 gap dynamics.
Venous-to-Arterial Carbon Dioxide Tension Difference (Delta PCO2)
Delta PCO2 (CO2 gap) is calculated as central venous PCO2 minus arterial PCO2 (PvCO2 - PaCO2) measured in mmHg. Paired arterial and central venous blood gas samples are collected simultaneously and analyzed within 10 minutes.
Time frame: Baseline
No study locations are listed for this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 533 non-industry observational studies under Diabetes Mellitus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 175. This study's planned 12 months is below that.
Counting every sponsor, half of 642 studies reached it within 36 months; a quarter within 14 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.